NCT06106295View on ClinicalTrials.gov

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 19, 2023

Primary Completion Date

January 31, 2028

Study Completion Date

February 1, 2028

Conditions
Autonomous Cortisol SecretionMild Autonomous Cortisol Secretion (MACS)
Interventions
DRUG

Metyrapone

250 to 1000 milligram (mg) orally in one or two doses in the evening (administered 4 and 2 hours prior to bed)

Trial Locations (1)

55905

Mayo Clinic Minnesota, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06106295 - Metyrapone for Mild Autonomous Cortisol Secretion (MACS) | Biotech Hunter | Biotech Hunter